Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · IEX Real-Time Price · USD
0.282
-0.024 (-7.85%)
At close: Apr 29, 2024, 4:00 PM
0.285
+0.003 (1.10%)
After-hours: Apr 29, 2024, 7:13 PM EDT
Daré Bioscience Revenue
In the year 2023, Daré Bioscience had annual revenue of $2.81M, a decrease of -71.92%. Revenue in the quarter ending December 31, 2023 was $1.81M.
Revenue (ttm)
$2.81M
Revenue Growth
-71.92%
P/S Ratio
10.10
Revenue / Employee
$122,082
Employees
23
Market Cap
28.35M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
Dec 31, 2022 | 10.00M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
Dec 31, 2012 | 625.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Retractable Technologies | 43.60M |
Palatin Technologies | 7.10M |
Evogene | 5.64M |
Singular Genomics Systems | 2.91M |
NeuroOne Medical Technologies | 2.82M |
IGC Pharma | 1.22M |
Lexaria Bioscience | 386.00K |
DARE News
- 6 days ago - Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - GlobeNewsWire
- 18 days ago - Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update - GlobeNewsWire
- 5 weeks ago - Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 - GlobeNewsWire
- 6 weeks ago - This overlooked corner of women's health could be a $350 billion market opportunity - CNBC
- 3 months ago - Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Executive Team and Board of Directors Changes - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Grant to Support Biotherapeutic Product Development - GlobeNewsWire